Understanding mitochondrial biology in alcohol-associated liver disease and cancer
A new perspective article by Niu and colleagues explains how megamitochondria, enlarged mitochondria found in alcohol-associated liver disease (ALD), initially protect liver cells but later contribute to inflammation, fibrosis, and liver cancer progression. Research from the Ding laboratory reveals that chronic alcohol exposure suppresses mitochondrial fission protein DRP1, leading to megamitochondria accumulation, which transitions from adaptive to pathogenic over time.
For decades, enlarged mitochondria called megamitochondria have been observed in liver biopsies of patients with alcohol-associated liver disease (ALD). A new study by Niu and colleagues, integrating findings from the Ding laboratory, proposes that these organelles initially serve a protective role but later drive inflammation, fibrosis, and liver cancer. The research shows that chronic alcohol exposure reduces the mitochondrial fission protein DRP1, causing impaired fragmentation and megamitochondria formation. Unlike previous assumptions, these enlarged mitochondria may temporarily improve mitochondrial function by increasing oxygen consumption, NAD+ production, and fatty acid oxidation in early-stage alcohol exposure. However, over time, accumulated megamitochondria become dysfunctional due to impaired mitophagy—the process of degrading damaged mitochondria. This leads to mitochondrial DNA release, activating the cGAS–STING immune pathway and promoting chronic liver injury and fibrosis. A key discovery is that disrupted mitochondrial dynamics alone can trigger liver tumor formation. Liver-specific DRP1 knockout mice developed fibrosis, inflammation, and spontaneous hepatic tumors, while restoring mitochondrial balance reduced tumor risk. The study also links mitochondrial dysfunction to altered pyrimidine metabolism, contributing to hepatocellular carcinoma (HCC) progression. These findings challenge the long-held view of megamitochondria as purely pathological, instead framing them as a dual-phase process—protective in early stages but harmful in chronic liver disease.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.